finanzen.net
30.06.2020 23:07

Mitsubishi Tanabe Pharma Canada Announces that Manitoba has Added the Company's Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Formulary

Folgen
Werbung

TORONTO, June 30, 2020 /CNW/ - Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), announced today that RADICAVA® (edaravone), an infusion treatment for amyotrophic lateral sclerosis (ALS), has been added to the Manitoba Drug Benefits and Interchangeability Formulary (special authorization), and the listing will take effect on July 16.

"The listing of RADICAVA is encouraging news for the Manitoba ALS community," said Atsushi Fujimoto, President, MTP-CA. "We thank the Government of Manitoba for providing eligible ALS patients access to the therapy and their ongoing commitment to those affected by ALS."

MTP-CA continues to have discussions with other provinces, territories and federal agencies regarding the listing of RADICAVA under additional publicly funded drug programs. In addition to the Manitoba Drug Benefits and Interchangeability Formulary (special authorization), RADICAVA also is listed on the:

  • Régie de l'assurance maladie du Québec (RAMQ) formulary (special authorization);
  • Ontario Drug Benefit Formulary (Exceptional Access Program);
  • Alberta Drug Benefit List (special authorization); and
  • New Brunswick Drug Plan (NBDP) formulary (special authorization).

RADICAVA is an intravenous infusion treatment for ALS, a rapidly progressive, neurodegenerative and fatal disease.1

About RADICAVA® (edaravone)

RADICAVA (edaravone) is indicated to slow the loss of function in patients with amyotrophic lateral sclerosis (ALS), as measured by the ALS Functional Rating Scale - Revised (ALSFRS-R).Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) through an iterative clinical development platform over a 13-year period. In 2015, edaravone was approved for use as a treatment for ALS in Japan and South Korea. RADICAVA was approved by the U.S. Food and Drug Administration in May of 2017. Marketing authorization was granted in Canada in October 2018 and Switzerland in January 2019.

About Mitsubishi Tanabe Pharma Canada, Inc.

Based in Toronto, Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA) with a goal to provide therapies for some of the most difficult-to-treat diseases, including ALS. For more information, please visit

www.mt-pharma-ca.com.

About Mitsubishi Tanabe Pharma America, Inc.

Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation's (MTPC) 100 percent owned U.S. holding company, Mitsubishi Tanabe Pharma Holdings America, Inc. MTPA is dedicated to delivering innovative products that address the unmet medical needs of patients in North America. It was established by MTPC to commercialize approved pharmaceutical products in North America with plans to expand its product line through collaborations with partners. For more information, please visit www.mt-pharma-america.com.

___________________________



1

National Institute of Neurological Disorders and Stroke. Amyotrophic Lateral Sclerosis (ALS) Information Page.


https://www.ninds.nih.gov/disorders/all-disorders/amyotrophic-lateral-sclerosis-als-information-page. Accessed March 2018.

2

RADICAVA® (edaravone) Canada Product Monograph. October 2019. https://www.mt-pharma-ca.com/our-product/

 

SOURCE Mitsubishi Tanabe Pharma Canada, Inc.

Werbung
Werbung
Werbung
Werbung
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

DAX deutlich schwächer -- Deutsche-Bank-Chef: Positive Trends haben im zweiten Quatal angehalten -- Palantir kündigt Börsengang an -- Lufthansa, HeidelbergCement, Talanx, Wirecard im Fokus

US-Regierung finanziert Corona-Impfstoffprojekt von Novavax mit 1,6 Milliarden Dollar. Briten wollen in Daimler-Fabrik in Hambach Geländewagen bauen. BaFin prüft möglichen Insiderhandel mit OSRAM-Aktien. DWS erwägt wohl Verkauf von IKS. Aktionäre wollen Abspaltung von Siemens Energy durchwinken. Apple setzt auf Oled-Bildschirme. Weitere positive Reaktion auf Übernahme durch JENOPTIK.

Umfrage

Deutschland debattiert über ein Ende der coronabedingten Maskenpflicht im Handel. Wie ist Ihre Meinung dazu?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Wirecard AG747206
NEL ASAA0B733
TeslaA1CX3T
Ballard Power Inc.A0RENB
Lufthansa AG823212
Deutsche Bank AG514000
BioNTech SE (spons. ADRs)A2PSR2
Daimler AG710000
CommerzbankCBK100
BayerBAY001
Plug Power Inc.A1JA81
Amazon906866
Deutsche Telekom AG555750
BASFBASF11
Infineon AG623100